Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Sees Large Decrease in Short Interest

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) was the target of a large decrease in short interest in July. As of July 31st, there was short interest totaling 262,477 shares, a decrease of 51.7% from the July 15th total of 542,999 shares. Based on an average daily trading volume, of 793,416 shares, the days-to-cover ratio is presently 0.3 days. Currently, 3.0% of the company’s stock are sold short.

Tvardi Therapeutics Price Performance

Shares of TVRD stock opened at $1.90 on Friday. Tvardi Therapeutics has a 1-year low of $1.50 and a 1-year high of $43.65. The stock’s 50-day moving average is $2.49 and its 200 day moving average is $3.19. The company has a market cap of $17.82 million, a P/E ratio of -0.68 and a beta of 0.39.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its earnings results on Friday, August 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.04). On average, analysts anticipate that Tvardi Therapeutics will post -2.32 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. UBS Group raised shares of Tvardi Therapeutics to an “outperform” rating and set a $10.00 price objective for the company in a research note on Wednesday, July 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Wednesday, July 8th. Raymond James Financial upgraded shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price target for the company in a report on Wednesday, July 8th. Wall Street Zen cut shares of Tvardi Therapeutics to a “strong sell” rating in a research report on Saturday, July 18th. Finally, BTIG Research dropped their price objective on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $18.00.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. GSA Capital Partners LLP acquired a new stake in Tvardi Therapeutics in the second quarter worth about $34,000. Arax Advisory Partners raised its stake in shares of Tvardi Therapeutics by 277.2% during the 4th quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock valued at $36,000 after buying an additional 6,173 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in shares of Tvardi Therapeutics in the 2nd quarter valued at about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Tvardi Therapeutics in the 2nd quarter worth approximately $43,000. Finally, HRT Financial LP purchased a new stake in Tvardi Therapeutics during the fourth quarter worth $47,000. Institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.